PD-1/PD-L1 inhibitory peptide C8
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model[1].
Product Specifications
UNSPSC
12352209
Target
PD-1/PD-L1
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Smiles
O=C(N[C@@H](CCCCN)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCCNC(N)=N)C(N4[C@@H](CCC4)C(N[C@@H](CO)C(N[C@H]5CCC(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CSSC[C@@H](C(O)=O)NC5=O)N
Molecular Formula
C51H72N14O14S2
Molecular Weight
1169.33
References & Citations
[1]Zhai W, et al., Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. Sci China Life Sci. 2021 Apr;64 (4) :548-562.
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P10826/
Scientific Category
Peptides
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
